Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report

V Paspalj; S Polterauer; N Poetsch; A Reinthaller; C Grimm; T Bartl

doi:10.1016/j.gore.2021.100817

Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report

Gynecol Oncol Rep. 2021 Jun 24:37:100817. doi: 10.1016/j.gore.2021.100817. eCollection 2021 Aug.

Authors

V Paspalj¹, S Polterauer^{1

2}, N Poetsch³, A Reinthaller^{1

2}, C Grimm^{1

2}, T Bartl¹

Affiliations

¹ Division of General Gynecology and Gynecologic Oncology, Department of Obstetrics and Gynecology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Austria.
² Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Vienna, Austria.
³ Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Austria.

Abstract

•Checkpoint inhibitor therapy affecting PD-L1 as treatment for advanced solid tumors.•Success in trial pembrolizumab therapy in multiresistant metastatic choriocarcinoma.•Long-term remission after pembrolizumab therapy in multiresistant choriocarcinoma.•Only six reported cases, one with comparable follow-up and outcome.

Keywords: CPI, checkpoint inhibitor; CT, computed tomography; Choriocarcinoma; ECOG, Eastern Cooperative Oncology Group; ETT, epithelioid trophoblastic tumor; GTD, gestational trophoblastic disease; GTN; GTN, gestational trophoblastic neoplasia; PD-1/PDL-1, programmed cell death-1/ programmed cell death ligand-1; PSTT, placental site trophoblastic tumor; Pembrolizumab; WHO, Worl Health Organization; cMRI, cerebral magnetic resonance imaging; β-HCG; β-HCG, beta-human chorionic gonadotropin.

Publication types

Case Reports